Alkermes PLC ALKS
News
Alkermes to Present New Data on Alixorexton and LUMRYZ® (sodium oxybate) at Sleep Europe 2026, Underscoring Leadership in Sleep Medicine Research
Alkermes Announces Positive Phase 1b Results Demonstrating Clinical Proof-of-Concept for ALKS 7290 in Adults With Attention-Deficit Hyperactivity Disorder (ADHD)
Alkermes Announces Appointment of Anne C. Whitaker to Board of Directors
Alkermes Announces Launch of 9th Annual Alkermes Pathways Research Awards® Program
The Lancet Neurology Publishes Data From Alkermes’ Positive Vibrance-1 Phase 2 Study of Alixorexton in Adults With Narcolepsy Type 1
Alkermes plc Reports Second Quarter 2026 Financial Results